Esketamine demonstrates superior analgesic efficacy and has the higher probability of being the optimal treatment for reducing early postoperative sleep disturbance incidence compared to dexmedetomidine.
In a network meta-analysis of 10 RCTs (645 patients), esketamine significantly reduced VAS pain scores at rest and during movement at 24 and 48 hours postoperatively. Both esketamine and dexmedetomidine reduced the incidence of PSD on the first postoperative day, but esketamine showed a stronger effect (RR=0.655 vs RR=0.773). Esketamine also improved subjective sleep outcomes (AIS, NRS) more effectively, likely due to its superior analgesia.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Esketamine demonstrates superior analgesic efficacy and has the higher probability of being the optimal treatment for reducing early postoperative sleep disturbance incidence compared to dexmedetomidine. The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).
The Claim
Esketamine demonstrates superior analgesic efficacy and has the higher probability of being the optimal treatment for reducing early postoperative sleep disturbance incidence compared to dexmedetomidine.
This conclusion is most relevant to: Adult surgical patients from RCTs conducted in China..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Comparative Efficacy of Dexmedetomidine and Esketamine on Postoperative Sleep Disturbances and Analgesia: A Systematic Review and Network Meta-Analysis. (Pain physician, 2026) —
How It Works
The proposed biological pathway:
- ▸Surgery induces postoperative sleep disturbance and heightened pain sensitivity.
- ▸Esketamine provides superior analgesia compared to dexmedetomidine.
- ▸Better pain control reduces pain-related sleep disruption.
- ▸Improved analgesia leads to reduced early PSD incidence and better subjective sleep quality.
Who Might Benefit
Evidence fit by population:
- ▸Adult surgical patients from RCTs conducted in China.
Recommended Dose
N/A (doses varied across included studies, not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸All included trials were conducted in China, limiting generalizability to other populations.
- ▸The number of included RCTs (10) and patients (645) is relatively small, and the PSG analysis included only 4 studies (n=182).
Frequently Asked Questions
Which drug is more effective for reducing postoperative pain?▼
Esketamine demonstrated significantly superior analgesic efficacy, reducing VAS pain scores at rest and during movement at 24 and 48 hours postoperatively compared to dexmedetomidine.
Does dexmedetomidine improve objective sleep architecture?▼
Yes, a supplementary meta-analysis of 4 PSG studies found that dexmedetomidine increased the percentage of stage N2 sleep (MD=13.0%) and showed a non-significant trend toward increasing stage N3 sleep (OR=2.99).
What is the primary outcome of this meta-analysis?▼
The primary outcomes were postoperative pain scores measured by VAS at 24 and 48 hours. Secondary outcomes included PSD incidence, AIS scores, and sleep quality on NRS.
Are these findings applicable to all surgical patients?▼
Caution is advised because all trials were conducted in China, and the sample size was relatively small. Further research in diverse populations is needed.
References
- 1.Jiang T, Zhao R, Zhang Y, Zhang R, Wu X, Jin L, Huang Y, Zhang Y, Czyzewski W, Staskiewicz G, Pruszynski K, Huang C, Zhu B. “Comparative Efficacy of Dexmedetomidine and Esketamine on Postoperative Sleep Disturbances and Analgesia: A Systematic Review and Network Meta-Analysis..” Pain physician, 2026. PMID: 42550519